Two genetic experimental approaches, de novo expression of parvalbumin (Parv) and overexpression of sarco(endo)plasmic reticulum Ca 2ϩ -ATPase (SERCA2a), have been shown to increase relaxation rates in myocardial tissue. However, the relative effect of Parv and SERCA2a on systolic function and on ␤-adrenergic responsiveness at varied pacing rates is unknown. We used gene transfer in isolated rat adult cardiac myocytes to gain a fuller understanding of Parv/SERCA2a function. As demonstrated previously, when Parv is expressed in elevated concentration (Ͼ0.1 mM), the transduced myocytes showed a reduction in sarcomere-shortening amplitude: 129 Ϯ 17, 81 Ϯ 8, and 149 Ϯ 14 nm for control, Parv, and SERCA2a, respectively. At physiological temperature, shortening amplitude responses of Parv and SERCA2a myocytes to the ␤-adrenergic agonist isoproterenol (Iso) were not statistically different from that of control myocytes. However, in SERCA2a myocytes, in which baseline was slightly elevated and the Iso-stimulated value was slightly lower, the increase in shortening was slightly less than in Parv or control myocytes: 108 Ϯ 14, 169 Ϯ 39, and 34 Ϯ 12% for control, Parv, and SERCA2a, respectively. In another test set, Parv myocytes had the strongest early postrest potentiation among all groups studied (rest time ϭ 2-10 s), and SERCA2a myocytes were the least sensitive to variations in stimulation rhythm. To replicate the deficient Ca 2ϩ removal observed in heart failure, we used 150 nM thapsigargin. Under these conditions, control myocytes exhibited slowed relaxation, whereas Parv myocytes retained their rapid kinetics, showing that Parv is still able to control relaxation, even when SERCA2a function is impaired. parvalbumin; sarco(endo)plasmic reticulum calcium-adenosinetriphosphatase 2a; diastolic dysfunction; gene transfer; thapsigargin; postrest potentiation
IMPAIRED CALCIUM HANDLING plays a crucial role in heart failure (21, 31) . In a normal heart, on sarcolemmal depolarization, a small amount of Ca 2ϩ enters the myocytes and binds to the ryanodine receptor (RyR) in the terminal cisternae of the sarcoplasmic reticulum (SR) (3) . This binding of Ca 2ϩ to RyR allows a massive release of Ca 2ϩ from the SR into the cytoplasm, which leads to mechanical contraction through interaction of Ca 2ϩ with the myofilaments. Relaxation follows removal of Ca 2ϩ from the cytoplasm (3). Three main proteins are involved in the control of Ca 2ϩ removal in cardiac myocytes: Na ϩ /Ca 2ϩ exchanger (NCX), sarco(endo)plasmic reticulum Ca 2ϩ -ATPase (SERCA2a), and phospholamban (PLB). SERCA2a is responsible for translocation of Ca 2ϩ from the cytoplasm to the SR. In most species, this is the dominant Ca 2ϩ removal mechanism: ϳ97% in rat and ϳ70% in human (2) . PLB acts as an inhibitor of SERCA2a. On PLB phosphorylation (e.g., via ␤-adrenergic stimulation), PLB dissociates from SERCA2a, leaving the pumps with an increased affinity for Ca 2ϩ (5) . Finally, NCX represents the main Ca 2ϩ removal route for Ca 2ϩ leaving the myocyte. Altered expression of these Ca 2ϩ -handling proteins has been associated with heart failure (31) . There is some debate on the magnitude and direction of the change in expression of these Ca 2ϩ -handling proteins in heart failure (21, 24, 32) . However, a decrease in SERCA2a-to-PLB and SERCA2a-to-NCX ratios appears to be a common feature of the failing myocardium (1, 16, 26, 35) .
Recently, two strategies featuring genetic manipulation have been proposed to restore Ca 2ϩ -handling function in myocytes from the failing heart (30): 1) restoration of the SERCA2a-to-PLB and/or SERCA2a-to-NCX ratio or 2) introduction of parvalbumin (Parv), a specialized Ca 2ϩ buffer (10) . The SERCA2a-to-PLB ratio has been manipulated by overexpression of SERCA2a (20) and expression of antisense PLB (6) and in PLB-knockout mice (27) . These approaches have restored Ca 2ϩ -handling function in a number of animal models of heart failure (13, 14, 17, 29, 37, 39) . However, in recent studies, increasing the SERCA2a-to-PLB ratio did not rescue the failing heart in all animal models (38, 41) . Paradoxically, in human studies, individuals expressing a nonfunctional mutated form of PLB (infinite SERCA2a-to-PLB ratio) have a high risk of developing cardiomyopathy early in adult life (8, 19, 40) .
Another strategy has employed the delayed Ca 2ϩ -buffering properties of Parv to increase the relaxation properties in cardiac muscle in vitro (11, 43) and in vivo (42) . The mechanism by which Parv increases relaxation performance in cardiac myocytes has been described elsewhere (10) . Briefly, Parv is an 11-kDa protein naturally found in fast-twitch skeletal muscles and in the brain, but not in the heart (15) . Parv functions as a delayed Ca 2ϩ buffer and has been shown to be associated with increased relaxation rates in skeletal muscle (23 (10) . Over an optimal Parv concentration range, the delayed Ca 2ϩ -buffering capacity of Parv is evident during the initial phase of Ca 2ϩ decay (increasing diastolic function), with no or little impact during the rising phase of the Ca 2ϩ transient, thus preserving systolic function (11) . As was the case for the first strategy (modification of the SERCA2a-to-PLB ratio), Parv also improved relaxation kinetics in animal models of diastolic dysfunction (9, 42, 43) .
In this study, we investigated the effect of modifications in the SERCA2a-to-PLB ratio via SERCA2a overexpression and expression of Parv on cardiac myocyte relaxation performance. The overall objective was to gain mechanistic insights into Ca 2ϩ -handling properties and to understand the consequences of SERCA2a and Parv gene transfer in important aspects of cardiac myocyte mechanical function. Accordingly, we used an experimental approach of gene transfer of Parv or SERCA2a in isolated rat adult cardiac myocytes (present study) combined with a theoretical analysis using mathematical modeling (12) .
Our aims in this experimental study were threefold. Our first aim was to determine whether the increase in relaxation rate caused by Parv-delayed Ca 2ϩ -buffering action could be maintained when the SERCA2a removal mechanism was impaired, as observed in human heart failure. As a mimetic of altered SERCA2a function in heart failure, we used a submaximal dose of thapsigargin (TG, 150 nM), a chemical compound that specifically inhibits SERCA2a (25, 45) . Under these conditions, we tested the hypothesis that although TG in control myocytes would cause a significant slowing of relaxation, the rapid relaxation kinetics observed in Parv-transduced myocytes would be unaltered by TG.
Our second aim was to determine the effects of Parv expression and SERCA2a overexpression in the presence of ␤-adrenergic stimulation. In normal myocardium, ␤-adrenergic stimulation markedly enhances heart pump performance. In heart failure, ␤-adrenergic stimulation responsiveness is reduced (2) . It is therefore of interest to investigate whether genetic manipulations in Ca 2ϩ -handling proteins would affect the ␤-adrenergic response in myocytes.
Our final aim focused on postrest potentiation (PRP) tests in Parv-and SERCA2a-transduced myocytes. PRP is defined as the contractile response, relative to a steady state, obtained after a resting period of given duration (2) . The nature of the PRP response is believed to be mainly dictated by the ability of the SR to reload Ca 2ϩ and by the refractory properties of the myocytes (2) . Although frequency response has been tested in Parv-transduced (11) and SERCA2a-overexpressing (37) myocytes, PRP offers additional insights into the interplay between modified Ca 2ϩ removal and SR Ca 2ϩ -reloading properties.
METHODS
Adult cardiac myocyte isolation, gene transfer, and primary culture. Cardiac myocytes were isolated from adult female SpragueDawley rats (200 g), and gene transfer was performed as described previously (11, 44) . Briefly, myocytes were plated and incubated for 2 h with no virus (control) or adenovirus containing the Lac-Z gene [200 -500 multiplicity of infection (MOI)], the human ␣-Parv gene (500 MOI), or the human SERCA2a gene (200 MOI). These doses have been shown to achieve maximal (95-100%) efficiency of gene transfer (11, 43) . The myocytes used for functional studies were transferred to stimulating chambers 18 h after gene transfer. The myocytes were then subjected to electrical stimulation (0.5-Hz frequency) sufficient to elicit contraction in 10 -20% of the myocytes and were kept in M199ϩ solution (Sigma) supplemented with 10 mM glutathione, 26.2 mM sodium bicarbonate, 0.02% bovine serum albumin, and 50 U/ml penicillin-streptomycin, with pH adjusted to 7.4, as described previously (11) .
The procedures used in this study were in agreement with the guidelines of the Internal Western blots. Each sample (ϳ40,000 myocytes) was collected from two coverslips 3 days after gene transfer and stored at Ϫ80°C in SDS-PAGE buffer (11) . The following primary antibodies were used for Western blotting: 5c5 (Sigma; 1:5,000 dilution) for actin, Parv19 (Sigma; 1:1,000 dilution) for Parv, MA3-922 (ABR; 1:1,000 dilution) for PLB, and MA3-919 (ABR; 1:1,000 dilution) for exogenous SERCA2 (MA3-919 does not recognize endogenous rat SERCA2a). Goat anti-mouse conjugated to horseradish peroxidase secondary antibody (catalog no. A-9917, Sigma; 1:1,000 dilution) was used as secondary antibody. Antibody C-20 (Santa Cruz Biotechnology; 1:100) combined with donkey anti-goat Ig-horseradish peroxidase (Santa Cruz Biotechnology; 1:500 dilution) was used to detect simultaneously the endogenous (rat) and exogenous (human via gene transfer) SERCA2a by enhanced chemiluminescence. In all cases, actin was used to normalize for loading (11) .
To estimate Parv concentration, the transduced cardiac myocyte samples were compared, after loading normalization, with samples collected from rat superior vastus lateralis (SVL) muscles. A Parv concentration of 0.4 mM was used for the SVL-positive control samples (18) .
We defined SERCA2a overexpression as the ratio of transduced SERCA2a to the endogenous level of SERCA2a. To quantify SERCA2a overexpression, we used two different methods. First, we used the antibody C-20, which detects the endogenous rat SERCA2a and the genetically transduced human SERCA2a. To calculate the amount of overexpression of human SERCA2a, we subtracted the amount of endogenous SERCA2a expressed in rat control myocytes from the total amount of SERCA2a expressed in the transduced myocytes and then normalized to the level of endogenous SERCA2a (see Eq. 1).
Second, we used the antibody MA3-919, which detects the transduced human SERCA2a, but not the endogenous rat SERCA2a. We were able to quantify the overexpression, because 1) this antibody also detects rabbit SERCA2a, and 2) the Ca 2ϩ uptake rate in rat myocytes is 2.5 times that in rabbit myocytes and SERCA2a affinity for Ca 2ϩ is the same in both species (25) . Assuming that the difference in function is due to a difference in the number of pumps, we derived the following equation: SERCA2a rat(endogenous) ϭ 2.5 ‫ء‬ SERCA2a rabbit(endogenous). Therefore, with this value, we can use the endogenous SERCA2a expression in rabbit myocytes, as detected with Western blot analysis, to quantify SERCA2a overexpression in our transduced rat myocytes (see Eq. 2). Both methods rely on the two following assumptions: 1) the antibody affinity for SERCA2a is the same across the different species used, and 2) the amount of endogenous SERCA2a in transduced myocytes remains the same as in the control myocytes over expression ϭ SERCA2a rat:transduced Sarcomere shortening and Ca 2ϩ transients. All experiments were performed at 37 Ϯ 1°C (unless specified otherwise) in M199ϩ solution. Coverslips were mounted on a custom microscope stage. Unloaded sarcomere shortening and Ca 2ϩ transients were measured simultaneously using the fluorescence and contractility system from Ionoptix (Milton, MA). Shortening data were sampled at 240 Hz, and Ca 2ϩ fluorescence was sampled at 1,000 Hz. The fluorescence ratio (ratio of excitation at 360 nm to excitation at 380 nm) was measured with fura 2-AM. For each myocyte, 8 -10 contractions were averaged and analyzed using the Ionoptix software. The fluorescence signal was filtered using a Savitzky-Golay filter (width ϭ 11, order ϭ 2). Ca 2ϩ fluorescence signals were normalized to a maximal value (1.0) after subtraction of background. For sarcomere length (SL) shortening measurements, time from stimulus to peak (Tp), times from peak to one-fourth, one-half, and three-fourths relengthening (Tp 1 ⁄4r, Tp 1 ⁄2r, and Tp 3 ⁄4r), amplitude (ampl), and relengthening maximal velocity (Ϫdl/dt) were measured. For PRP experiments, time from stimulus to one-half relengthening (Ts 1 ⁄2r) was also evaluated. For Ca 2ϩ fluorescence measurements, the following parameters were measured: time from stimulus to peak (Tp Ca) and times from stimulus to one-fourth, one-half, and three-fourths decay (Ts 1 ⁄4d, Ts 1 ⁄2d, and Ts 3 ⁄4d).
Three independent sets of experimental data were collected: TG, Iso, and PRP. For the first data set (TG), the stimulation-and-measurement protocol was optimized from results obtained in pilot studies (unpublished data), in which we found that 150 nM TG produced a nearly maximal inhibition effect, the drug effect was stable with 7-15 min of incubation, and continuous pacing empties the SR content, annihilating contractions. The protocol is as follows: myocytes were loaded for 5 min with Ca 2ϩ fluorescence indicator [5 M fura 2-AM with 0.01% Pluronic F-127 (both from Molecular Probes)], and after washout, an additional 5 min were allowed for deesterification. The myocytes were then stimulated for 1 min at 0.2 Hz before the baseline measurement was made (also at 0.2 Hz). Then the myocytes were treated with 150 nM TG in the quiescent state (no stimulation) for 8 min. At the end of the TG incubation period, the myocytes were again stimulated for 1 min at 0.2 Hz before measurements were made. TG (Sigma) was diluted to 500 M in DMSO as stock solution. The stock solution was diluted in M199ϩ solution. Measurements were made at two external Ca 2ϩ concentrations: 1.8 and 5.0 mM. The same protocol was used for the second set of data (Iso), except for the external Ca 2ϩ concentration (fixed at 1.8 mM), dose (10 nM Iso), and incubation time (1-2 min). The dose was selected to produce a strong inotropic effect with a minimal number of fibrillating myocytes, and the incubation time was the minimal amount of time required for the myocytes to stabilize for temperature. In addition to measurements at 37°C, measurements at room temperature (22 Ϯ 2°C) were performed to emphasize the Iso effect on relaxation kinetics.
For the final data set (PRP), the myocytes were loaded with fura 2-AM as described above. The experimental protocol (see Fig. 3A ) follows this sequence: conditioning train of 10 pulses (interpulse duration ϭ 1 s), 2 min of rest, another train of 10 prepulses (interpulse duration ϭ 1 s), a variable rest period of duration T, and a train of 10 postpulses (interpulse duration ϭ 1 s). The ratio of postpulse 1 to the average of the last three prepulses (prepulses 8 -10) was used to characterize PRP.
Statistical analysis. All statistical analysis was performed using GraphPad Prism software. For experiments where myocytes were studied as populations, one-way ANOVA was used to determine any significant differences among multiple groups of data. When significant differences were detected, a Newman-Keuls multiple comparison test was performed to find which groups were different from each other (P Ͻ 0.05). For experiments in which individual myocytes were used as their own baseline, a two-tailed paired t-test was used. Values are means Ϯ SE.
RESULTS
Gene transfer. Gene transfer to isolated rat adult cardiac myocytes in primary culture has been shown to be a highly efficient and synchronized means of acute genetic engineering (11, 28) . Typically, Ͼ95% of the adult cardiac myocytes express the delivered gene product (44) . In this study, all experiments were conducted 3 days after gene transfer to yield a robust expression of Parv (11) and SERCA2a ( Fig. 1) . Figure  1 shows representative Western blots, and, as expected, Parv was present only in the Parv-transduced myocytes. The level of expression was 34.5 Ϯ 11.4% (n ϭ 11) of the Parv level in SVL muscle samples. With the assumption of 0.4 mM Parv in SVL (18) , this leads to an estimated 0.138 Ϯ 0.046 mM in the transduced cardiac samples. Two different antibodies were used to detect SERCA2a. The first (anti-SERCA2a#1 in Fig. 1 , antibody C-20) detected endogenous SERCA2a and human SERCA2a obtained through gene transfer. Although a small increase in total SERCA2a expression could be seen in some Western blot results, it did not reach statistical significance. However, with use of the second antibody (anti-SERCA2a#2, antibody MA3-919), it was possible to uniquely detect the human SERCA2a expressed by gene transfer. As described in METHODS, we used nontransduced rabbit cardiac myocytes to quantify the level of exogenous SERCA2a in rat myocytes. On average, the transduced rat myocytes expressed 1.15 Ϯ 0.18 times the level of endogenous SERCA2a found in rabbit cardiac myocytes (when normalized to actin). Knowing that the amount of SERCA2a expression in rabbit is ϳ40% of that in rat myocytes (25), we can indirectly obtain an overexpression factor of 46 Ϯ 7% (Eq. 2). The reason for the discrepancy Fig. 1 . Western blot analysis of Ca 2ϩ -handling proteins in rat adult cardiac myocytes. Ctrl, control myocytes; Lac-Z, Parv, and SERCA2a, myocytes transduced with Lac-Z, parvalbumin, and sarco(endo)plasmic reticulum Ca 2ϩ -ATPase, respectively; SVL, superior vastus lateralis muscle (positive control for Parv). Parv was detected only in Parv-transduced myocytes and at a level comparable to that in SVL samples. Anti-SERCA2a#1 shows endogenous and overexpressed SERCA2a; anti-SERCA2a#2 shows only SERCA2a produced via gene transfer. No changes were observed in expression of phospholamban (PLB; P, pentamer; M, monomer). Actin was used to control for loading. between these two methods is unclear. Because the second method clearly indicates that the overexpressed SERCA2a is present only in the transduced myocytes and that a strong phenotype is present in these myocytes (see Figs. 2-8) , it is possible that a difference in affinity for the endogenous rat SERCA2a and exogenous human SERCA2a by antibody C-20 could help explain our findings. The two methods used for quantifying SERCA2a overexpression give values of 15% and 46%. Because antibody MA3-919 clearly shows overexpression of human SERCA2a and given some uncertainties regarding the exact avidity of antibody C-20 between human and rat SERCA2a, we interpret the reason for the accelerated relaxation kinetics of SERCA2a myocytes to be due to 15-46% overexpression of SERCA2a. No significant changes were detected in the PLB level among the different groups of myocytes.
Three independent sets of functional measurements were collected: PRP measurements, single twitches with and without TG, and single twitches with and without Iso. To evaluate the functional efficiency of the gene transfer of Parv and SERCA2a, we used the baseline data of one of these data sets (0 nM TG and 1.8 mM extracellular Ca 2ϩ ; Table 1 , Fig. 2 ). In Fig. 2A , representative traces of normalized sarcomere shortening/relengthening highlight the ability of Parv and SERCA2a to increase relaxation kinetics. Ca 2ϩ fluorescence was measured simultaneously using the Ca 2ϩ indicator fura 2-AM. In both myocyte groups, the early part of the Ca 2ϩ fluorescence transient decay was accelerated compared with control, but only SERCA2a-transduced myocytes were able to maintain this acceleration during the late phase of the Ca 2ϩ fluorescence decay. A summary of the data is presented in Fig. 2 , C and D. As shown previously (11), on day 3 after gene transfer, sarcomere-shortening amplitude was reduced in Parv-transduced myocytes (Fig. 2C) . This phenomenon has been attributed to some Ca 2ϩ buffering during the rising phase of the Ca 2ϩ transient by Parv (11) and is reduced when Parv is expressed in lower concentration. SERCA2a showed a tendency for higher shortening amplitude than control myocytes, but this did not reach statistical significance. Taken together, these data show that, under the conditions used in the present Values are means Ϯ SE of total number of myocytes [for 0 nm thapsigargin (TG)], the number of myocytes that survived 150 nm TG treatment for sarcomere-shortening and all fluorescence measurements (1st n value), and the number of myocytes for which 150 nm TG sarcomere-shortening amplitude was Ն25% of its baseline (2nd n value) used for all kinetics sarcomere-shortening data. Parv, parvalbumin; SERCA2a, sarco(endo)plasmic reticulum Ca 2ϩ -ATPase; RR, relative ratio [average of (TG data/baseline) ϫ 100, where each myocyte is its own control]; Ampl, amplitude; Ϫdl/dt, return velocity; Tp, time to peak; Tp 1/4r, Tp 1/2r, and Tp 3/4r, times from peak to 1 ⁄4, 1 ⁄2, and 3 ⁄4 relengthening; TpCa, time to fluorescence peak; Ts 1/4d, Ts 1/2d, and Ts 3/4d, time from stimulus to 1 ⁄4, 1 ⁄2, and 3 ⁄4 decay. study, Parv-and SERCA2a-transduced myocytes showed similar acceleration of relaxation, with Parv having a tendency to reduce amplitude of contraction when expressed at high levels.
PRP. PRP is the measurement of recovery or decay from the steady state of the contractile force (or shortening) after a quiescent period (2) . The protocol used in this study is presented in Fig. 3A (bottom; see METHODS) . Although all control and Parv myocytes and most of the SERCA2a myocytes exhibited a flat or decreasing prepulse sequence, some of the SERCA2a myocytes (2 of 10) behaved very differently. Although these myocytes appeared normal (rod shape and good striation pattern), they showed a very strong increasing pattern (Fig. 3A) . It was difficult to quantitatively assess the portion of the myocytes behaving "atypically," but they have been noticed in almost every individual experiment involved in this study. Because of this "atypical" response, these traces have been separated from the "typical" traces in all reported results. Figure 3B shows the PRP of the sarcomere-shortening amplitude. The results are plotted as the ratio of postpulse 1 to the prepulse steady state (average of the last 3 prepulses) as a Typical "normal" responses for control (n ϭ 9), Parv (n ϭ 8), and SERCA2a (n ϭ 8) myocytes are shown, as well as atypical "abnormal" SERCA2a myocyte response (n ϭ 2). B: summary of sarcomere-shortening (SS) amplitude PRP data. PRP was measured as postpulse 1 data over the average of prepulses 8, 9, and 10. Parv myocytes had the most potentiation, control and "normal" SERCA2a myocytes had a similar trend, but to a lesser extent, and "abnormal" (SE not shown; n ϭ 2) SERCA2a had a negative potentiation at long rest period. C: summary of the time from stimulus to one-half relengthening (Ts 1 ⁄2r) PRP data. Kinetics data followed a trend similar to that of amplitude data. Values are means Ϯ SE.
function of the duration of the rest period (logarithmic scale): 100% indicates no potentiation, and Ͼ100% indicates a positive potentiation response. Control and typical SERCA2a-overexpressing myocytes show a small increase at a shorter rest period (2-10 s), with values increasing to 178.6 Ϯ 11.6% and 154.0 Ϯ 35.5% at 120 s, respectively. Parv myocytes showed a very high potentiation at 120 s (206.7 Ϯ 20.2%). Part of this potentiation is due to the fact that Parv myocytes started from a lower baseline than controls. However, even at 2 s, Parv myocytes showed significant potentiation (124.5 Ϯ 6.4%). For completeness, SERCA2a myocytes with atypical responses are also shown. These atypical SERCA2a myocytes show a flat and elevated potentiation (at low T, i.e., 2-10 s), followed by a negative potentiation at longer rest intervals (25-120 s). The kinetics, as measured by the time from stimulus to one-half relengthening, followed a trend similar to the amplitude, but to a lesser extent (Fig. 3C) . Another way to analyze these data is to observe how the 10 prepulses vary from the first to the last (Fig. 4) . This is equivalent to examining how the myocytes transition to a steady state after a long rest period. All the prepulse trains were obtained after 120 s of rest. For each myocyte, six sets of measurements were obtained and averaged. In Fig. 4A , representative traces show the difference in control myocytes between pulse 1 and pulse 9 for Ca 2ϩ fluorescence and sarcomere shortening. In both cases, the amplitude reduction was accompanied, to a lesser extent, by a decrease in T s 1 ⁄2r or T s 1 ⁄2d. The summaries of the sarcomere-shortening amplitude and T s 1 ⁄2r are presented in Fig. 4 , B and C, respectively. The amplitude curves for the control and SERCA2a myocytes showed a progressive decrease from pulse 1, with SERCA2a myocytes showing a flatter response. In contrast, Parv-treated myocytes showed an abrupt decline from pulse 1 to pulse 2 and then stabilized for the subsequent pulses with a smaller decline. Similar trends were observed in T s 1 ⁄2r. When the change in T s 1 ⁄2r was plotted against the change in amplitude (100% ϭ no change from prepulse 1), a strong and similar correlation was found in all groups (Fig. 4D) . The magnitude of change in amplitude was larger than the magnitude of change in kinetics, and SERCA2a myocyte data were clustered in the region of minimal change (ϳ80 -100% ampl), whereas Parv myocytes were clustered around the other end of the trend lines (ϳ40 -60% ampl). In summary, the PRP data suggest that although expression of Parv and overexpression of SERCA2a accelerate relaxation similarly, they modify the ability of the myocyte to handle changes in pacing rhythm differently. The quantitative analysis of these PRP data is complex and well suited for mathematical modeling interpretation (12) .
Inotropic and lusitropic response. To address how Parv-and SERCA2a-transduced myocytes respond to ␤-adrenergic stimulation, the myocytes were treated with 10 nM Iso ( Table 2 , Fig. 5 ). Figure 5A shows representative sarcomere-shortening traces for control, Parv, and SERCA2a myocytes at 37°C with and without Iso. Parv and control myocytes showed comparable increases in amplitude, whereas SERCA2a showed a blunted increase. The summary in Fig. 5B confirms these results. Indeed, SERCA2a myocytes started with a baseline amplitude slightly (but not significantly) more elevated than control. In the presence of 10 nM Iso, the SERCA2a shortening amplitude did not reach the level obtained in control myocytes; however, they showed a significant increase of 33.7 Ϯ 11.8%. In contrast, the Parv myocytes started with a reduced baseline amplitude and reached an amplitude slightly more elevated than the SERCA2a myocytes for an increase of 169.3 Ϯ 38.9% (comparable to control and Lac-Z myocytes: 107.9 Ϯ 31.8% and 149.7 Ϯ 44.9%, respectively; Table 2 ). At 37°C, the Ca 2ϩ fluorescence data (Fig. 5D ) showed faster T s 1 ⁄2d for baseline value in Parv and SERCA2a than in control myocytes. However, 10 nM Iso did not significantly change these values in Parv and SERCA2a myocytes, although it had a significant effect on the Lac-Z and control myocytes, reducing T s 1 ⁄2d to Parv and SERCA2a values. Although a similar trend was seen in sarcomere-shortening kinetics (T p 1 ⁄2r; Fig. 5C ), the magnitude of the change due to Iso was small and significant only for the Lac-Z group.
To further investigate positive lusitropic effects (i.e., increase in relaxation rate) of de novo expression of Parv and overexpression of SERCA2a, we repeated the same experiments at room temperature (22 Ϯ 2°C; Table 2 , Fig. 6 ). Figure  6A shows two representative control myocyte shortening responses to 10 nM Iso. When normalized to the same amplitude, the myocytes at 37°C showed slight changes in relaxation parameters, whereas at 22°C there was a marked acceleration of the relaxation kinetics. There was a smaller difference in the amplitude response among the different myocyte groups at 22°C than at 37°C. The change in T p 1 ⁄2r kinetics was more pronounced at 22°C for control and Lac-Z myocytes in the presence of 10 nM Iso (Fig. 6C) . At 37°C (Fig. 5C) , the Parv and SERCA2a myocytes did not increase their already rapid relaxation rates in the presence of Iso. The Ca 2ϩ fluorescence kinetic data showed similar effects.
We also examined another strategy known to create positive inotropy by elevating external Ca 2ϩ concentration (from 1.8 to 5.0 mM). The results are presented in Fig. 7 and were obtained from data presented in Table 1 (data at 1.8 and 5.0 mM Ca 2ϩ were obtained from another set of myocytes). SERCA2a shortening amplitude was blunted compared with the other groups (Fig. 7A) , whereas Parv and SERCA2a myocytes retained their faster kinetics with elevated external Ca 2ϩ (Fig. 7B) . The results show that Parv myocytes and, to a lesser extent, SERCA2a myocytes respond positively to inotropic interventions (Iso or elevated Ca 2ϩ ), but their already rapid kinetics could not be further accelerated in the presence of a lusitropic agent (Iso).
Chemical model of diastolic dysfunction. We used a submaximal dose of TG to chemically mimic diastolic dysfunction as observed in heart failure. We also found that, in addition to causing diastolic dysfunction, TG also reduced sarcomere- Values are means Ϯ SE of number of myocytes used for sarcomere shortening (1st n value) and for fluorescence (2nd n value). See Table 1 footnote for definition of abbreviations.
shortening amplitude when used in rat cardiac myocytes. A submaximal dose of 150 nM TG was used to create diastolic dysfunction and to minimize contractile amplitude reduction. In addition to measurements at 1.8 mM (normal M199ϩ solution), we also obtained measurements at 5.0 mM external Ca 2ϩ to increase the sarcomere-shortening amplitude in the presence of TG to improve the signal-to-noise ratio. Results are presented in Table 1 and Fig. 8 .
For all conditions taken together, Ͼ91% (106 of 116) of the myocytes survived the TG treatment (Table 1) . Although all surviving myocytes were used to calculate shortening amplitude and Ca 2ϩ fluorescence data, only those that retained Ն25% of the shortening amplitude of the pre-TG treatment (73%, or 77 of 106) were kept for sarcomere-shortening kinetic analysis, because low signal-to-noise ratio (or even the absence of contraction) makes evaluation of the kinetic parameters difficult (or impossible). showed an increase of only 9.1 Ϯ 6.1% and 22.2 Ϯ 12.1%, respectively. When a two-tailed paired t-test was conducted, only Parv myocytes did not show a significant increase in T s 1 ⁄4d and T s 1 ⁄2d (at 1.8 and 5.0 mM external Ca 2ϩ ). The average attenuation of sarcomere-shortening amplitude was similar in all groups under all conditions and was 40.4 -55.5% (Table 1) . At low external Ca 2ϩ , only the late relaxation kinetic parameter T p 3 ⁄4r showed significant slowing in control myocytes (Fig.  8C) . At elevated Ca 2ϩ , in control myocytes the relative increase from baseline in all measured kinetic parameters (T p 1 ⁄4r, T p 1 ⁄2r, and T p 3 ⁄4r) was statistically significant (Fig. 8E) . Again, only Parv myocytes were able to preserve their kinetic properties in the presence of TG in all sarcomere-shortening kinetic parameters. The data suggest that Parv could have a protective role in maintaining relaxation properties under conditions where the main Ca 2ϩ sequestration mechanism is partially impaired, as seen in heart failure.
DISCUSSION
We have reported a direct comparison between the effects of Parv expression de novo and SERCA2a overexpression in isolated rodent cardiac myocytes under a variety of experimental conditions. Using unloaded sarcomere shortening and Ca 2ϩ fluorescence, we found that 1) Parv-and SERCA2a-transduced myocytes have similar effects on shortening kinetics, 2) SERCA2a myocytes better preserve contractile amplitude than Parv myocytes (at high levels of expression), and 3) although the shortening amplitude in the presence of 10 nM Iso is similar in all groups at physiological temperature, the increase in shortening amplitude of Parv myocytes in response to ␤-adrenergic stimulation was comparable to that of control myocytes, whereas the response of SERCA2a myocytes was reduced. In addition, we showed that Parv corrects diastolic dysfunction in a chemical model where only the SR Ca 2ϩ -ATPase is impaired.
TG as a chemical model of diastolic dysfunction. TG is derived from the plant Thapsia garganica (45) , has a very high affinity for SERCA2a (K d Ͻ 1 nM) (25) , and is a very specific inhibitor of SERCA2a. In this study, the intent was to mimic diastolic dysfunction by using a submaximal dose of TG to create a partial inhibition of SERCA2a function, a feature often seen in heart failure (see the introduction).
A number of cellular changes occur during heart failure. Indeed, in addition to the impairment observed in Ca 2ϩ removal, myosin heavy chain isoform changes from ␣ to ␤ (4), several K ϩ currents (e.g., I to and I k1 ) are downregulated (32) , and the increase in Ca 2ϩ diastolic level activates calmodulindependent signaling events, which can lead to hypertrophy (7, 33) . Isolation of the effect specific to Ca 2ϩ removal deficiency in this context becomes difficult. Even more difficult is the task of understanding the basic effects of the addition or modification of Ca 2ϩ -handling proteins to this complex pathophysiological system. The use of TG to mimic diastolic dysfunction allows the specific isolation of impaired SR Ca 2ϩ uptake to directly study the biophysical effects of adding a delayed Ca 2ϩ buffer such as Parv. However, this model is not suitable for use in studying the effect of overexpressing SERCA2a in diastolic dysfunction, because TG would also affect the newly expressed Ca 2ϩ pumps. One consequence of using TG in rodent cardiac myocytes to mimic diastolic dysfunction is the progressive emptying of the SR. This also creates systolic dysfunction. This situation can be corrected by using TG combined with some inotropic strategy. In this study, we used elevated external Ca 2ϩ to partially improve the sarcomere-shortening amplitude in the presence of TG. A direct comparison between data without TG at 1.8 mM external Ca 2ϩ and data with 150 nM TG at 5.0 mM external Ca 2ϩ reveals a strong diastolic dysfunction with almost no diminution in systolic function (Table 1) . Other strategies, such as an augmentation of Ca 2ϩ cellular entry via an increase in action potential duration or a reduced Ca 2ϩ cellular exit via a reduced NCX function, could produce similar results (12) .
TG does not affect Parv-mediated rapid relaxation. In the presence of 150 nM TG, control (and Lac-Z-transduced) myocytes exhibited slower sarcomere-relengthening kinetics, especially in the late phase of the cycle. However, when Parv myocytes were treated with the same TG dose, no significant changes were observed (Table 1, Fig. 8 ). The sarcomereshortening behavior of these two groups in the presence of TG could be explained better by first analyzing their Ca 2ϩ transient properties.
Ca 2ϩ fluorescence data showed that all phases of the Ca 2ϩ transient decay were slowed in control myocytes when TG was applied. In contrast, Parv-transduced myocytes were able to maintain their already rapid kinetics in the presence of TG, at least in the first 50 -60% of the decay. The basis for this result is hypothesized as follows. In rat control myocytes, SERCA2a pumps are responsible for almost all Ca 2ϩ sequestration (2) and, therefore, drive the entire shape of the Ca 2ϩ transient decay. When these pumps become partially inhibited by TG, the entire decay is slowed. However, with Parv, the early part of the decay is mostly dominated by the delayed buffering of Ca 2ϩ by Parv. In this case, inhibition of SERCA2a has little influence on this part of the response. In the late part of the Ca 2ϩ fluorescence decay, preservation of the rapid kinetics in Parv myocytes was reduced. In the absence of TG, it has been shown that Parv slowly releases its bound Ca 2ϩ in the myoplasm during the late decay phase in myocytes (10) . The rate of this reaction is dictated by a combination of the SERCA2a sequestration properties and the Ca 2ϩ off-rate from Parv. When TG is added to the Parv-transduced myocytes, the Ca 2ϩ off-rate is unaffected but the SERCA2a uptake rate is diminished, resulting in an even slower late phase of Parv-transduced myocytes. However, this late phase appears to be below the threshold required to create mechanical contraction, because it has not been observed in any of the sarcomere-shortening measurements presented in this study.
On the basis of this model of diastolic dysfunction, we can speculate that, in addition to correction of diastolic function, as seen previously in some animal models (42, 43) , Parv could potentially offer some degree of protection against downregulation of Ca 2ϩ pumps in vivo, as seen in human heart failure (1, 16) .
Parv and SERCA2a: ␤-adrenergic response and systolic function. Although de novo expression of Parv and overexpression of SERCA2a operate through very distinct mechanisms, both increase relaxation rates to a similar extent during single contractions. However, their response differs in at least two important aspects: responsiveness to ␤-adrenergic stimulation and management of contractile amplitude.
In this study, Parv-transduced myocytes showed a reduction in sarcomere-shortening amplitude compared with control myocytes. In a previous study (11), we found that Parv buffers most of its Ca 2ϩ in the early phase of the Ca 2ϩ transient decay. However, when Parv is expressed at higher concentrations, it can also affect the rising phase of the Ca 2ϩ transient, resulting in reduced Ca 2ϩ transient and sarcomere-shortening amplitudes (11) . In the same study, we demonstrated that there was an optimal range of Parv concentration for which Parv increases relaxation rates without affecting contractile amplitude (11) . This phenomenon occurs at ϳ0.01-0.1 mM Parv (or at ϳ2.5 days after gene transfer) for rat cardiac myocytes in vitro. In the present study, we focused on Parv concentrations above this optimal range (ϳ0.14 mM, 3.0 days after gene transfer) to have a greater effect on relaxation kinetics. In comparison, under the conditions used in this study, SERCA2a-transduced myocytes showed only a tendency to increase shortening amplitude, without reaching statistical significance. Other studies have shown no change or an increase in amplitude, depending on the species studied and experimental conditions (6, 20) . In particular, the increase in amplitude seems to be more apparent at higher stimulation frequency (6) . In this study, our use of a low stimulus frequency (0.2 Hz) might explain this relatively small increase in sarcomere-shortening amplitude in SERCA2a-overexpressing myocytes. Pharmaceutical treatments that have negative inotropic effects on the myocardium, such as ␤-blockers, have been shown to help patients with heart failure (22, 36) . It is therefore possible that, in addition to its positive impact on relaxation rate, Parv attenuation effects on contractile function may also be beneficial. Interestingly, not only did Szatkowski et al. (42) not find any reductions in systolic function in the Parv-transduced rat heart in vivo, they reported an increase in pressure development after gene transfer. Clearly, more research is required to determine the optimal inotropy/lusitropy strategy in vivo.
As mentioned above, the ␤-adrenergic response is critical in managing the wide range of pumping capacity of the heart. In this study, we examined the dynamic range of shortening amplitude when the Parv-and SERCA2a-transduced myocytes were treated with 10 nM Iso. Parv-transduced and control myocytes showed a comparable increase in sarcomere-shortening amplitude, whereas in SERCA2a myocytes the amplitude increased only moderately ( Table 2) . Part of the explanation for this limited increase in SERCA2a-transduced myocytes is the slightly more elevated baseline amplitude than in control myocytes. However, at 10 nM Iso, there was a tendency for SERCA2a myocytes to have lower shortening amplitude than controls, but it did not reach statistical significance. A possible explanation for this phenomenon is that the level of SERCA2a in overexpressing myocytes is increased without any change in PLB content (6, 20) , most likely leaving a large portion of the new pumps uncoupled to PLB and, therefore, less sensitive to Iso. A possible limitation of the present study is that measurements were made under unloaded conditions and that mechanical load could affect the baseline properties and the responsiveness to ␤-adrenergic stimulation.
In conclusion, we used TG as a chemical means to mimic cellular diastolic dysfunction and found that Parv myocytes retained their rapid relaxation properties. This study also provides, for the first time, a detailed characterization of rat cardiac myocytes transduced with Parv under a variety of conditions: ␤-adrenergic stimulation, elevated external Ca 2ϩ , lowered temperature, and PRP tests. A direct comparison with SERCA2a overexpression was performed, highlighting the strengths and possible limitations of each approach; SERCA2a overexpression has a reduced range of modulation by ␤-adrenergic stimulation, whereas Parv de novo expression is more susceptible to decrease in contractile function, at least in vitro.
This study, combined with our mathematical analysis (12), helps clarify the effects of adding new Ca 2ϩ -handling proteins in normal and diseased cardiac myocytes. It remains to be determined whether the results and conclusions found in vitro in rodent myocytes will translate to the organ level of larger mammals, including humans.
